Clinical Presentation, Management, and Advances in Treatment of Sickle Cell Retinopathy

Screening and monitoring can prevent visual morbidity.

By Ishrat Ahmed, MD, PhD, Adrienne W. Scott, MD

Rho Kinase Inhibitors for Diabetic Macular Edema

A sustained-release implant has promise for both DME and Wet AMD.

By Michael A. Singer, MD, Jennifer Gallagher, MD

Plasma Kallikrein Inhibition in Diabetic Macular Edema

Targeting a novel, VEGF-independent pathway of DME could preserve and recover vision.

By Andreas Maetzel, MD, PhD, Edward P. Feener, PhD

THR-149 and THR-687 for Diabetic Macular Edema

New therapeutics target RGD integrins and the plasma kallikrein system.

By Aamir A. Aziz, BS, Majid Khan, BS, Arshad M. Khanani, MD, MA

Bacterial Sequestration by Conjunctival Mucous

Removal prior to transconjunctival procedures may lower bacterial load.

By Steven R. Bodine, MD, Charles W. Mango, MD

The Expanding Role of Anti-VEGF in the Management of Diabetic Retinopathy

Changes could represent a paradigm shift in treatment.

By Christina Y. Weng, MD, MBA

Developments in Teleophthalmology for Diabetic Retinopathy

Diabetic eye disease is a prime target for remote diagnosis and management.

By Suzanne Michalak, MD, Majda Hadziahmetovic, MD

Intraocular Long-Term Anti-Inflammatory Treatment for Noninfectious Uveitis

Sustained-release therapy could prevent long-term, irreversible structural damage and vision loss.

By Veeral S. Sheth, MD, MBA, FACS

SUBSPECIALTY NEWS: Trial data on gene therapy, proposed Medicare cuts, FDA clearance of an AI diagnostic for DR, and more.

By Jerry Helzner, contributing editor

New Pathways for Diabetic Macular Edema Therapy

Several potential therapies are in clinical trials.

By Carl D. Regillo, MD, FACS

UPFRONT: Anti-VEGF for DR in the Real World

By Peter K. Kaiser, MD

CLINICAL TRIAL DOWNLOAD: Discussing Inflammation From Brolucizumab

A conversation on next steps and clinical implications.

By Yasha Modi, MD

NEW PRODUCT APPLICATIONS: Tracking Medication Inventory Easily and Efficiently

A range of features meet the needs of a variety of practice types.

By Karen Appold, contributing writer

CLINICAL TRIAL UPDATE

Independently Owned, Consolidation, and Private Equity for Retina Practices

Consider the shifting ophthalmology landscape.

By Jonathan Feistmann, MD